格雷夫茲病市場：現況分析與預測（2024-2032）

格雷夫茲病市場預計將呈現約5%的成長率。這主要歸功於有助於早期發現格雷夫茲病的診斷工具和技術的技術進步，以及對生物製藥公司投資的增加。例如，2022年6月，生物製藥公司Sling Therapeutics, Inc.發起了由TPG旗下The Rise Fund領投的3,500萬美元A輪融資。這筆資金將支持一項 2b 期臨床試驗，評估該公司的研究藥物 linsitinib 作為甲狀腺眼疾 (TED) 的治療方法。 TED 主要影響女性，由格雷夫茲病引起的甲狀腺功能亢進患者受影響最大。

依治療類型，市場分為抗甲狀腺藥物、β受體阻斷劑、放射性碘治療、手術（甲狀腺切除）、輔助治療及新興治療。其中，抗甲狀腺藥物類別預計將在預測期內出現顯著增長，為治療甲狀腺功能亢進（格雷夫茲病的關鍵症狀）提供非侵入性且有效的治療選擇。這些藥物的作用是抑制甲狀腺激素的產生，幫助荷爾蒙水平恢復正常並緩解症狀。此外，為提高這些藥物的功效和安全性而進行的持續研究和開發正在促進該領域的發展，進一步推動格雷夫茲病市場。

依最終使用者劃分，市場分為醫院、專科診所、門診手術中心及家庭醫療保健。其中，醫院作為診斷、治療和管理的主要護理點，是格雷夫茲病市場成長的主要動力。醫院提供專業內分泌科醫生、先進的診斷測試以及甲狀腺手術和放射性碘治療等治療。它還促進患者教育和支持計劃，以提高疾病意識和管理。醫院基礎設施和資源可實現高效的護理服務，對於全球有效的格雷夫茲病管理至關重要。

為了更瞭解格雷夫茲病的市場介紹，市場為北美（美國、加拿大等北美地區）、歐洲（德國、英國、法國、西班牙、義大利等歐洲地區） 、亞太地區（中國，根據全球其他地區（日本、印度、亞太地區其他地區）和其他地區的全球影響力進行分析。在預測期內，北美佔據主要佔有率。該地區先進的醫療基礎設施有利於格雷夫茲病的早期診斷和有效管理，為市場擴張做出了重大貢獻。民眾和醫療保健專業人員對自體免疫疾病的認識程度較高，可以及時進行幹預，並增加了對診斷和治療解決方案的需求。此外，製藥公司和學術機構對研發的大量投資正在促使生物製劑和先進抗甲狀腺藥物等創新療法的推出，進一步提振市場。此外，政府的支持措施和有利的報銷政策正在增加患者獲得尖端治療的機會，並推動北美市場的成長。

目錄

第一章市場介紹

• 市場定義
• 主要目標
• 利害關係人
• 限制

第二章研究方法或前提

• 調查過程
• 調查方法
• 受訪者簡介

第 3 章執行摘要

• 行業概況
• 依細分市場進行預測
  • 市場成長的力量
• 區域展望

第 4 章市場動態

• 促進因素
• 機會
• 抑制因素
• 趨勢
• PESTEL 分析
• 需求方分析
• 供給面分析
  • 併購
  • 投資場景
  • 產業洞察：主要新創公司及其獨特策略

第五章價格分析

• 區域價格分析
• 影響價格的因素

第 6 章2022-2032 年全球格雷夫茲病市場收入

第 7 章市場分析：依治療類型

• 抗甲狀腺藥物
• β受體阻斷劑
• 放射性碘治療
• 手術（甲狀腺切除術）
• 輔助治療
• 新興療法

第 8 章市場分析：依最終使用者劃分

• 醫院
• 專科診所
• 門診手術中心
• 家庭治療

第 9 章市場考量：依地區

• 北美
  • 美國
  • 加拿大
  • 其他北美地區
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 其他領域

第10章價值鏈分析

• 邊際分析
• 進入市場的公司名單

第十一章競爭態勢

• 競爭對手儀表板
• 競爭市場定位分析
• 波特五力分析

第十二章公司簡介

• Merck & Co., Inc.
  • 公司概況
  • 主要財務數據
  • SWOT分析
  • 產品組合
  • 近期動態
• Abbott
• Pfizer Inc.
• GSK plc.
• AbbVie Inc.
• RLC Labs
• Mylan N.V.
• F. Hoffmann-La Roche Ltd
• Medtronic
• Ascendis Pharma

第 13 章縮寫與先決條件

第14章附錄

The Graves' disease market encompasses the diagnosis, treatment, and management of Graves' disease, an autoimmune disorder that leads to hyperthyroidism. Characterized by symptoms such as anxiety, rapid heartbeat, weight loss, and goiter, Graves' disease requires effective management to prevent serious complications. The market is driven by several growth factors, including the increasing prevalence of autoimmune disorders, advancements in diagnostic technologies, and the development of more effective treatment options, such as anti-thyroid medications, radioactive iodine therapy, and thyroid surgery. Additionally, rising awareness about thyroid disorders, an aging global population, and improved healthcare infrastructure further contribute to the expansion of the graves' disease market.

The market for graves disease is set to exhibit a growth rate of about 5%. This is mainly due to the technological advancements in diagnostic tools and techniques that are aiding in the early detection of graves' disease and rising investment in biopharmaceutical companies. For instance, in June 2022, Sling Therapeutics, Inc., a biopharmaceutical company launched a USD 35 million Series A financing led by TPG's The Rise Fund. The funds will support a Phase 2b clinical trial evaluating the company's investigational drug, linsitinib, for the treatment of thyroid eye disease (TED). TED predominantly affects women, and most frequently affects people with hyperthyroidism due to Graves' disease.

Based on the treatment type, the market is divided into anti-thyroid medications, beta-blockers, radioactive iodine therapy, surgery (thyroidectomy), adjunctive therapies, and emerging treatments. Among them, the anti-thyroid medications category is expected to grow at a significant rate during the forecast period by offering a non-invasive and effective treatment option for managing hyperthyroidism, a key symptom of Graves' disease. These medications work by inhibiting the production of thyroid hormones, helping to restore hormone levels to normal and alleviate symptoms. Additionally, ongoing research and development efforts to improve the efficacy and safety of these medications contribute to the growth of this segment, further driving the graves disease market.

Based on the end-user, the market is segmented into hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Homecare Settings. Among these, hospitals are significantly driving the growth of the graves disease market by serving as the primary point of care for diagnosis, treatment, and management. Hospitals provide access to specialized endocrinologists, advanced diagnostic tests, and treatments like thyroid surgery and radioactive iodine therapy. They also facilitate patient education and support programs, improving disease awareness and management. Hospitals' infrastructure and resources enable efficient care delivery, making them crucial for effective Graves' disease management worldwide.

For a better understanding of the market adoption of graves disease, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America accounts for the major share during the forecast period. The region's advanced healthcare infrastructure facilitates early diagnosis and effective management of Graves' disease, contributing significantly to market expansion. High awareness levels among the population and healthcare professionals about autoimmune disorders ensure timely intervention, thereby increasing the demand for diagnostic and therapeutic solutions. Additionally, substantial investments in research and development by pharmaceutical companies and academic institutions are leading to the introduction of innovative treatments, such as biologics and advanced anti-thyroid medications, further propelling the market. Moreover, supportive government initiatives and favorable reimbursement policies enhance patient access to cutting-edge treatments, fostering market growth in North America.

Some of the major players operating in the market include Merck & Co., Inc.; Abbott; Pfizer Inc.; GSK plc.; AbbVie Inc.; RLC Labs; Mylan N.V.; F. Hoffmann-La Roche Ltd; Medtronic; Ascendis Pharma.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Global Graves Disease Market
• 2.2. Research Methodology of the Global Graves Disease Market
• 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

• 3.1. Industry Synopsis
• 3.2. Segmental Outlook
  • 3.2.1. Market Growth Intensity
• 3.3. Regional Outlook

4.MARKET DYNAMICS

• 4.1. Drivers
• 4.2. Opportunity
• 4.3. Restraints
• 4.4. Trends
• 4.5. PESTEL Analysis
• 4.6. Demand Side Analysis
• 4.7. Supply Side Analysis
  • 4.7.1. Merger & Acquisition
  • 4.7.2. Investment Scenario
  • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

• 5.1. Regional Pricing Analysis
• 5.2. Price Influencing Factors

6.GLOBAL GRAVES DISEASE MARKET REVENUE (USD MN), 2022-2032F

7.MARKET INSIGHTS BY TREATMENT TYPE

• 7.1. Anti-Thyroid Medications
• 7.2. Beta-Blockers
• 7.3. Radioactive Iodine Therapy
• 7.4. Surgery (Thyroidectomy)
• 7.5. Adjunctive Therapies
• 7.6. Emerging Treatments

8.MARKET INSIGHTS BY END-USER

• 8.1. Hospitals
• 8.2. Specialty Clinics
• 8.3. Ambulatory Surgical Centers
• 8.4. Homecare Settings

9.MARKET INSIGHTS BY REGION

• 9.1. North America
  • 9.1.1. U.S.
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe
  • 9.2.1. Germany
  • 9.2.2. U.K.
  • 9.2.3. France
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia-Pacific
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Rest of Asia-Pacific
• 9.4. Rest of World

10.VALUE CHAIN ANALYSIS

• 10.1. Marginal Analysis
• 10.2. List of Market Participants

11.COMPETITIVE LANDSCAPE

• 11.1. Competition Dashboard
• 11.2. Competitor Market Positioning Analysis
• 11.3. Porter Five Forces Analysis

12.COMPANY PROFILED

• 12.1. Merck & Co., Inc.
  • 12.1.1. Company Overview
  • 12.1.2. Key Financials
  • 12.1.3. SWOT Analysis
  • 12.1.4. Product Portfolio
  • 12.1.5. Recent Developments
• 12.2. Abbott
• 12.3. Pfizer Inc.
• 12.4. GSK plc.
• 12.5. AbbVie Inc.
• 12.6. RLC Labs
• 12.7. Mylan N.V.
• 12.8. F. Hoffmann-La Roche Ltd
• 12.9. Medtronic
• 12.10. Ascendis Pharma

13.ACRONYMS & ASSUMPTION

14.ANNEXURE